Business
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025
WATERTOWN, Mass., August 11, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2025.
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2190,"height":732,"url":"https://media.zenfs.com/en/business-wire.com/b78912eabc9f985611973121644aec1d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pdK9_B1iw7cYd.xV.RWvYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b78912eabc9f985611973121644aec1d","width":960,"height":321},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/E4MVpyas1L_Dfx68nL0QpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b78912eabc9f985611973121644aec1d","width":1200,"height":401}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"On Track to Report Topline Data for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in September","length":155,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"On Track to Select a STAT6 Development Candidate in 2H 2025","length":59,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Conducting IND Enabling Studies of EPS-1421, an Oral KIT Inhibitor Candidate, in Development for the Treatment of Chronic Spontaneous Urticaria and Other Mast Cell Driven Diseases","length":179,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Operations Supported by Cash and Marketable Securities Totaling $204.1 Million at June 30, 2025, as well as Continuing Retained Royalties","length":137,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":530,"olType":false},{"type":"text","content":"WATERTOWN, Mass., August 11, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2025.","length":309,"tagName":"p"},{"type":"text","content":""This past quarter we continued to make steady progress across our pipeline, marked by the completion of enrollment in the RSVHR trial, a proof-of-concept study of zelicapavir in high-risk adults infected with RSV. These patients face a heightened risk of serious illness from RSV, but currently there are no approved anti...